Schizophrenia and schizoaffective disorder treated with high doses of olanzapine

被引：20
|
作者：
Fanous, A [1 ]
Lindenmayer, JP [1 ]
机构：
[1] NYU, Sch Med, New York, NY 10016 USA
来源：
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 1999年 / 19卷 / 03期
关键词：
D O I：
10.1097/00004714-199906000-00015
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：275 / 276
页数：2
相关论文
共 50 条
  • [31] Steady state concentrations after standard and higher doses of oral olanzapine in acutely ill patients with schizophrenia or schizoaffective disorder with suboptimal prior response
    Kinon, Bruce J.
    Volavka, Jan
    Bergstrom, Richard F.
    Kurtz, Darcie L.
    Stauffer, Virginia L.
    Edwards, Beth
    Liu-Seifert, Hong
    Chen, Lei
    Adams, David H.
    Lindenmayer, Jean-Pierre
    McEvoy, Joesph P.
    Buckley, Peter F.
    Lieberman, Jeffrey A.
    Meltzer, Herbert Y.
    Wilson, Daniel
    Citrome, Leslie
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S115 - S116
  • [32] ARE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER SEPARABLE?
    Heinrichs, Walter
    Hartman, Leah
    Pinnock, Farena
    Mashhadi, Farzaneh
    Ciantar, Sarah
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S368 - S368
  • [33] Anosognosia in schizophrenia and schizoaffective disorder
    Amador, XF
    Seckinger, RA
    Kasapis, C
    Limpert, C
    Yale, SA
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 10 - 10
  • [34] Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder
    Lambert, Tim J. R.
    EVIDENCE-BASED MENTAL HEALTH, 2009, 12 (02) : 50 - 50
  • [35] SAFETY AND EFFICACY OF LONG-TERM ASENAPINE VERSUS OLANZAPINE IN SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER PATIENTS
    Schoemaker, J.
    Naber, D.
    Jansen, W.
    Panagides, J.
    Emsley, R.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [36] Tolerability, safety and pharmacokinetics of aripiprazole at high doses in adults with a diagnosis of schizophrenia or schizoaffective disorder - A pilot study.
    Mallikaarjun, S
    Bramer, SL
    Kornhauser, D
    Saha, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P17 - P17
  • [37] Prediction of response in 160 patients with schizophrenia, schizoaffective and bipolar disorder after olanzapine or risperidone treatment
    Bonaccorso, S.
    Bobo, W. V.
    Chen, Y.
    Jayathilake, K.
    Meltzer, H. Y.
    EUROPEAN PSYCHIATRY, 2008, 23 : S155 - S156
  • [38] Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder
    Schoemaker, J.
    Naber, D.
    Vrijland, P.
    Panagides, J.
    Emsley, R.
    PHARMACOPSYCHIATRY, 2010, 43 (04) : 138 - 146
  • [39] Safety and efficacy of long-term asenapine versus olanzapine in schizophrenia or schizoaffective disorder patients
    Schoemaker, J.
    Stet, L.
    Naber, D.
    Panagides, J.
    Emsley, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 238 - 238
  • [40] Physiology of schizophrenia, bipolar disorder, and Schizoaffective disorder
    Martin, Laura F.
    Hall, Mei-Hua
    Ross, Randal G.
    Zerbe, Gary
    Freedman, Robert
    Olincy, Ann
    AMERICAN JOURNAL OF PSYCHIATRY, 2007, 164 (12): : 1900 - 1906
12345